Hyaline cartilage

Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan.

Retrieved on: 
Wednesday, July 7, 2021

A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.

Key Points: 
  • A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210707005420/en/
    Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.)
  • EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:
    (i) Yielding Hyaline cartilage native to articular joints:

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

Retrieved on: 
Wednesday, June 30, 2021

The initiation of the HST 003 clinical trial as a treatment for regeneration of knee cartilage marks a major milestone for Histogen as we focus on developing best in class orthopedic therapeutics with our novel regenerative medicine platform technology, said Richard W. Pascoe, Histogens President and CEO.

Key Points: 
  • The initiation of the HST 003 clinical trial as a treatment for regeneration of knee cartilage marks a major milestone for Histogen as we focus on developing best in class orthopedic therapeutics with our novel regenerative medicine platform technology, said Richard W. Pascoe, Histogens President and CEO.
  • This double-blind placebo-controlled trial is designed to evaluate the safety and efficacy of hECM implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.
  • Primary and secondary endpoints will include safety assessments, MRI to evaluate cartilage regeneration, and Knee Injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) scores to evaluate pain and joint function.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

Global Regenerative Medicine for Cartilage Market Report 2021: COVID-19 Impacts, Growth and Changes - Long-term Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021

The regenerative medicine for cartilage is used for hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration.\nEurope was the largest region in regenerative medicine for cartilage in 2020.

Key Points: 
  • The regenerative medicine for cartilage is used for hyaline cartilage repair and regeneration, elastic cartilage repair and regeneration, and fibrous cartilage repair and regeneration.\nEurope was the largest region in regenerative medicine for cartilage in 2020.
  • Global Regenerative Medicine for Cartilage Market, Segmentation by Treatment Modality, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.2.
  • Global Regenerative Medicine for Cartilage Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.5.
  • Global Regenerative Medicine for Cartilage Market, Segmentation by End-Use, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n'

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Retrieved on: 
Monday, March 15, 2021

We anticipate initiating the Phase 1/2 trial in the second quarter of 2021 utilizing funding provided by the $2M grant from the Department of Defense.

Key Points: 
  • We anticipate initiating the Phase 1/2 trial in the second quarter of 2021 utilizing funding provided by the $2M grant from the Department of Defense.
  • Histogens human extracellular matrix, or hECM, is intended for regenerating hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the bodys own stem cells.
  • Studies conducted by outside experts have demonstrated thatHST-003is anti-inflammatory, angiogenic, and can stimulate the growth of stem cells in damaged areas to induce tissue regeneration.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform

Retrieved on: 
Monday, March 8, 2021

Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors.

Key Points: 
  • Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors.
  • They hope this technology will improvise the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments.
  • The lab environment makes the chondrocytes, many a time, grow as fibrocartilage, whereas, hyaline cartilage is the ideal type of tissue required, which contributes to weight bearing function of the joint.
  • On the contrary, Dr Katoh`s team used a polymer scaffold that retains chondrocyte secreted HA to enhance their growth as a tissue, yielding higher HA content.

Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

Retrieved on: 
Tuesday, January 19, 2021

Histogen has not yet received the written notice of its clinical hold from the FDA, which the FDA expects to provide to the company by February 12, 2021.

Key Points: 
  • Histogen has not yet received the written notice of its clinical hold from the FDA, which the FDA expects to provide to the company by February 12, 2021.
  • Based upon the verbal communication with FDA, they indicated that the clinical hold is due to pending CMC information that is required to complete their review.
  • Histogen plans to work diligently with the FDA to seek the release of the clinical hold and provide updated guidance on any potential impact to the HST-003 program once the written notice from FDA is received.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

AlloSource's ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting

Retrieved on: 
Friday, January 15, 2021

During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.

Key Points: 
  • During the session titled ProChondrix CR: Cryopreserved off-the-shelf Hyaline Cartilage Allograft.
  • Dr. Argo, with Beacon Orthopaedics and Sports Medicine in Cincinnati, Ohio, will highlight his experience repairing osteochondral defects of the knee with AlloSource's allograft.
  • A potentially debilitating condition, chondral injuries are a common issue that affect nearly one million people in the United States annually.
  • "This meeting provides a great opportunity to share my experience with ProChondrix for cartilage defects in the knee," said Dr. Argo.

Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee

Retrieved on: 
Wednesday, September 16, 2020

Regenerating uniform functional hyaline cartilage is critical to restoring normal function for military personnel and civilians alike.

Key Points: 
  • Regenerating uniform functional hyaline cartilage is critical to restoring normal function for military personnel and civilians alike.
  • Histogens HST-003 has demonstrated hyaline cartilage regeneration in three different in vivo animal models conducted by orthopedic experts.
  • Approximately 900,000 Americans are affected by knee cartilage injuries annually, with 200,000 requiring surgical interventioni.
  • The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

Cartilage Repair & Regeneration Market Outlook to 2022 - Increased R&D Spending for Advancements in Knee Cartilage Repair - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 22, 2020

This report provides a detailed analysis of the current and future market scenario of the global cartilage repair and regeneration market.

Key Points: 
  • This report provides a detailed analysis of the current and future market scenario of the global cartilage repair and regeneration market.
  • Furthermore, in terms of application, the hyaline cartilage repair and regeneration market accounts for the largest share in 2016.
  • It is also expected to be the fastest-growing application segment in the cartilage repair and regeneration market.
  • Thus, the report provides a comprehensive analysis of cartilage repair & regeneration technology, which will enable investors to design suitable business strategies to target this market.

Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program

Retrieved on: 
Wednesday, April 15, 2020

We have now tested HST 003 in three animal models, and the results have been consistent and exciting, said Dr. Gail Naughton, Founder and Chief Science Officer of Histogen.

Key Points: 
  • We have now tested HST 003 in three animal models, and the results have been consistent and exciting, said Dr. Gail Naughton, Founder and Chief Science Officer of Histogen.
  • In vivo preclinical studies showed that treating full thickness osteochondral lesions with HST 003 resulted in hyaline cartilage and mature bone formation in rats (ODriscoll score p
  • The results seen in these latest preclinical studies support the advancement of our key HST 003 program, said Richard Pascoe, Chairman and CEO of Histogen.
  • Approximately 18 million U.S. patients suffer from knee osteoarthritis, a debilitating degenerative disease characterized by softening and disintegration of cartilage.